BriaCell Therapeutics Corp. Warrant financials
$0.1950+25.56%
Close Sep 28, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Jul 31 |
|---|---|
| Revenue | $0.00 |
| Gross profit | $0.00 |
| Gross margin | — |
| Operating income | -$27.2M |
| Net income | -$26.3M |
| Net margin | — |
| Diluted EPS | $-62.19 |
| EBITDA | -$27.1M |
| Operating cash flow | -$28.2M |
| Free cash flow | -$28.2M |
| Diluted shares | 0.4M |
Balance sheet
| Period end | Jul 31 |
|---|---|
| Cash & equivalents | $10.5M |
| Short-term investments | $7.4M |
| Total debt | $0.00 |
| Total assets | $21.6M |
| Total liabilities | $4.3M |
| Shareholders' equity | $17.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology